{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-24-000054","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.331470+00:00","generated_at":"2026-06-02T04:06:02.214186+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Humacyte Q1 net loss $31.9M; FDA grants Priority Review for HAV, PDUFA Aug 10, 2024","bullets":["Net loss $31.9M vs $37.0M YoY; no revenue; cash $115.5M, up from $35.1M net provided.","BLA for HAV in vascular trauma accepted with Priority Review; PDUFA date Aug 10, 2024.","Raised ~$43M net from public offering in March 2024; additional $20M draw from Oberland facility.","Total operating expenses $26.6M flat QoQ; R&D $21.3M up from $17.3M YoY.","Preparations for US launch ongoing: hired VP Sales, completed Budget Impact Model, seeking ICD-10 code."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-24-000054","json":"https://secwatch.observer/filing/0001818382-24-000054.json","markdown":"https://secwatch.observer/filing/0001818382-24-000054.md","text":"https://secwatch.observer/filing/0001818382-24-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000054/0001818382-24-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000054/huma-20240510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:06:02.214186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84b69c7a4d97bada3bde4bfe2eebdbb2f7fcaf24","claim":"Humacyte, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 10, 2024, Humacyte, Inc. issued a press release regarding its financial results for its fiscal first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000054/0001818382-24-000054-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}